AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. Export

@article{Borst1994, abstract = {Antigenic profiles in AML that have generally accepted prognostic significance, and allow treatment stratification, have not yet been defined. In a previous report of Ashman et al., the proto-oncogene c-kit defined by binding of the moab YB5.B8 was expressed on about one third of AML cases, mainly of the undifferentiated FAB-subtypes and associated with poor prognosis and overall survival. In this study, the moab 17F11 also directed against the c-kit structure stained 41/47 AML and 6/8 CML blast specimens, whereas all investigated 40 ALL samples were c-kit negative. c-kit was not restricted to any particular, undifferentiated FAB-subtype, but found in 9/9 AML-M0/M1, 18/19 AML-M2, 0/1 AML-M3, 11/13 AML-M4 and 3/5 AML-M5 subtypes. Immunophenotypical analysis showed no restriction of c-kit expression to immature, CD34+ precursors, but c-kit was also expressed on CD4+ CD34- precursor cells differentiating towards the monocyte lineage. In addition, multi-color labelings revealed an extraordinary heterogeneity of concomitant antigen expression on c-kit+ cells 10/36 c-kit+ CD34+ samples expressing CD56 and 16/36 c-kit+ CD34+ samples being CD7 positive; two c-kit+ CD34+ specimens carried the B-cell antigen CD19. In correlation to clinical outcome c-kit expression as single parameter was not predictive for poor response to therapy and short survival as previously suggested.}, address = {Second Department of Internal Medicine, Medical University Clinic, T\"{u}bingen, Germany.}, author = {Reuss-Borst, M. A. and B\"{u}hring, H. J. and Schmidt, H. and M\"{u}ller, C. A.}, citeulike-article-id = {1401523}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/7508533}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=7508533}, issn = {0887-6924}, journal = {Leukemia}, keywords = {aml, c-kit}, month = {February}, number = {2}, pages = {258--263}, posted-at = {2007-06-20 19:55:13}, priority = {2}, title = {AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/7508533}, volume = {8}, year = {1994} }

TY - JOUR ID - Borst1994 L3 - citeulike-article-id:1401523 N2 - Antigenic profiles in AML that have generally accepted prognostic significance, and allow treatment stratification, have not yet been defined. In a previous report of Ashman et al., the proto-oncogene c-kit defined by binding of the moab YB5.B8 was expressed on about one third of AML cases, mainly of the undifferentiated FAB-subtypes and associated with poor prognosis and overall survival. In this study, the moab 17F11 also directed against the c-kit structure stained 41/47 AML and 6/8 CML blast specimens, whereas all investigated 40 ALL samples were c-kit negative. c-kit was not restricted to any particular, undifferentiated FAB-subtype, but found in 9/9 AML-M0/M1, 18/19 AML-M2, 0/1 AML-M3, 11/13 AML-M4 and 3/5 AML-M5 subtypes. Immunophenotypical analysis showed no restriction of c-kit expression to immature, CD34+ precursors, but c-kit was also expressed on CD4+ CD34- precursor cells differentiating towards the monocyte lineage. In addition, multi-color labelings revealed an extraordinary heterogeneity of concomitant antigen expression on c-kit+ cells 10/36 c-kit+ CD34+ samples expressing CD56 and 16/36 c-kit+ CD34+ samples being CD7 positive; two c-kit+ CD34+ specimens carried the B-cell antigen CD19. In correlation to clinical outcome c-kit expression as single parameter was not predictive for poor response to therapy and short survival as previously suggested. IS - 2 JF - Leukemia SN - 0887-6924 AD - Second Department of Internal Medicine, Medical University Clinic, Tübingen, Germany. EP - 263 TI - AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. VL - 8 SP - 258 KW - aml KW - c-kit AU - Reuss-Borst, MA AU - Bühring, HJ AU - Schmidt, H AU - Müller, CA PY - 1994/02// UR - http://view.ncbi.nlm.nih.gov/pubmed/7508533 ER -